These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 9259089

  • 1. Treatment of superficial bladder cancer with intravesical chemotherapy.
    Badalament RA, Farah RN.
    Semin Surg Oncol; 1997; 13(5):335-41. PubMed ID: 9259089
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, Gore JL.
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [Abstract] [Full Text] [Related]

  • 4. Intravesical chemotherapy--frequency of instillation.
    Smith PH.
    Prog Clin Biol Res; 1985 May; 185B():57-68. PubMed ID: 3929271
    [No Abstract] [Full Text] [Related]

  • 5. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [Abstract] [Full Text] [Related]

  • 6. The biology and treatment of superficial bladder cancer.
    Torti FM, Lum BL.
    J Clin Oncol; 1984 May; 2(5):505-31. PubMed ID: 6427417
    [Abstract] [Full Text] [Related]

  • 7. Intravesical chemotherapy of superficial bladder cancer.
    Lum BL.
    Recent Results Cancer Res; 1983 May; 85():3-36. PubMed ID: 6408716
    [No Abstract] [Full Text] [Related]

  • 8. Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience.
    Malmström P.
    Eur Urol; 2000 May; 37 Suppl 1():16-20. PubMed ID: 10575267
    [Abstract] [Full Text] [Related]

  • 9. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M, McGarry R, Kupelnick B.
    Anticancer Res; 2001 May; 21(1B):765-9. PubMed ID: 11299841
    [Abstract] [Full Text] [Related]

  • 10. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A, Bonacina P, Butti A, Cappoli S, Esposito N, Invernizzi S, Librizzi A, Locatelli G.
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [Abstract] [Full Text] [Related]

  • 11. Intravesical drug delivery. Pharmacokinetic and clinical considerations.
    Highley MS, van Oosterom AT, Maes RA, De Bruijn EA.
    Clin Pharmacokinet; 1999 Jul; 37(1):59-73. PubMed ID: 10451783
    [Abstract] [Full Text] [Related]

  • 12. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [Abstract] [Full Text] [Related]

  • 13. Intravesical therapy for superficial bladder cancer.
    Baselli EC, Greenberg RE.
    Oncology (Williston Park); 2000 May; 14(5):719-29; discussion 729-31, 734, 737. PubMed ID: 10853462
    [Abstract] [Full Text] [Related]

  • 14. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA, Jimenez León J, Martinez-Pineiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    Prog Clin Biol Res; 1989 May; 310():237-52. PubMed ID: 2505269
    [Abstract] [Full Text] [Related]

  • 15. Intravesical chemotherapy for superficial bladder cancer.
    Koontz WW.
    Urology; 1984 Apr; 23(4 Suppl):79-81. PubMed ID: 6424298
    [No Abstract] [Full Text] [Related]

  • 16. Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
    Sekine H, Fukui I, Yamada T, Yamada T, Kojima S, Ohshima H.
    J Urol; 1996 Jan; 155(1):94-8; discussion 98-9. PubMed ID: 7490908
    [Abstract] [Full Text] [Related]

  • 17. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP.
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract] [Full Text] [Related]

  • 18. Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
    Faraj K, Chang YH, Rose KM, Habermann EB, Etzioni DA, Blodgett G, Castle EP, Humphreys MR, Tyson Ii MD.
    Can J Urol; 2019 Oct; 26(5):9922-9930. PubMed ID: 31629441
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer.
    Shapiro A, Ratliff TL, Oakley DM, Catalona WJ.
    J Urol; 1984 Jan; 131(1):139-42. PubMed ID: 6418894
    [Abstract] [Full Text] [Related]

  • 20. [Superficial bladder cancer: prophylaxis of recurrence and progression].
    Miyanaga N, Akaza H, Koiso K.
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2369-74. PubMed ID: 1719939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.